Roche joins Ab­b­Vie in step­ping on Ver­tex's turf, bet­ting $96M on an al­ter­na­tive CF ap­proach

James Sabry’s lat­est deal spree is tak­ing Roche back to a field where Genen­tech nabbed one of its first FDA ap­provals: cys­tic fi­bro­sis.

Turn­ing to En­ter­prise Ther­a­peu­tics out of Brighton, Eng­land, Roche is ac­quir­ing a port­fo­lio of TMEM16A po­ten­tia­tors, which promis­es to treat all CF pa­tients re­gard­less of CFTR geno­type as well as oth­er res­pi­ra­to­ry dis­eases. The up­front comes in at $96.76 mil­lion (£75 mil­lion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER